4
Changes in Ownership
Jade Biosciences, Inc. Filed Acc 0001415889-23-006376
CHIEF SCIENTIFIC OFFICER sold 2,250 shares at an average $18.20 ($40,942)
- CHIEF SCIENTIFIC OFFICER acquired 2,250 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
NIVEN RALPH · CHIEF SCIENTIFIC OFFICER
Table I: Non-derivative
4 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2023-04-05 | Exercise or conversion : show line 1 in the form | +650 | $1.74 | $1,131 | 2,259 | D |
| 2023-04-05 | Exercise or conversion : show line 2 in the form | +1,600 | $2.14 | $3,424 | 3,859 | D |
| 2023-04-05 | Sale : show line 3 in the form | −1,715 | $17.91 | $30,721 | 2,144 | D |
| 2023-04-05 | Sale : show line 4 in the form | −535 | $19.11 | $10,221 | 1,609 | D |
| Open-market sales · 2,250 sh · avg $18.20 · $40,942 | ||||||
Table II: Derivative
5 lines| Date | Transaction | Shares | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| 2023-04-05 | Exercise or conversion : show line 5 in the form Stock Option (Right to Buy) | −450 | $1.74 | 2030-09-03 | 450 | 20,058 | D |
| 2023-04-05 | Exercise or conversion : show line 6 in the form Stock Option (Right to Buy) | −200 | $1.74 | 2030-09-03 | 200 | 12,688 | D |
| 2023-04-05 | Exercise or conversion : show line 7 in the form Stock Option (Right to Buy) | −200 | $2.14 | 2031-04-01 | 200 | 14,494 | D |
| 2023-04-05 | Exercise or conversion : show line 8 in the form Stock Option (Right to Buy) | −650 | $2.14 | 2031-04-01 | 650 | 44,058 | D |
| 2023-04-05 | Exercise or conversion : show line 9 in the form Stock Option (Right to Buy) | −750 | $2.14 | 2031-04-01 | 750 | 52,982 | D |
Loading xslF345X04/form4-04072023_060401.xml…